Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Infectious disease · Phase II

Infectious disease programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs 365

Quick answer

Infectious disease Phase II programs: NovaPharmaNews indexes 365 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Pipeline programs

Page 2 of 8

  1. AT-527

    Atea Pharmaceuticals

    COVID-19

    phase 2 small molecule terminated

    2 trials

  2. AT-777

    Atea Pharmaceuticals

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  3. AVI-4065 Injection

    Sarepta Therapeutics

    Hepatitis C

    phase 2 small molecule terminated

    1 trial

  4. Alvelestat

    Mereo BioPharma Group plc

    Covid19

    phase 2 small molecule completed

    1 trial

  5. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  6. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial

  7. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial

  8. Aprepitant injectable emulsion

    Heron Therapeutics

    COVID-19

    phase 2 small molecule terminated

    1 trial

  9. BEVACIZUMAB

    Pari Pharma GmbH

    Adult patients with persistent dyspnea more than 3 months after acute COVID-19 infection.

    phase 2 small molecule active

    1 trial

  10. BMS-955176

    ViiV Healthcare B.V.

    HIV Infections

    phase 2 small molecule terminated

    1 trial

  11. BRII-179

    Vir Biotechnology

    For Treatment of Chronic Hepatitis B Virus Infection

    phase 2 mab active

    1 trial

  12. BRII-835 (VIR-2218)

    Vir Biotechnology

    Hepatitis B, Chronic

    phase 2 small molecule completed

    1 trial

  13. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

  14. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  15. Bamlanivimab

    Vir Biotechnology

    COVID-19

    phase 2 small molecule completed

    1 trial

  16. Behavior Therapy

    BRIGHT MINDS BIOSCIENCES INC.

    The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

    phase 2 other terminated

    1 trial

  17. Behavioral Drug and Risk Counseling (BDRC)

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Risk Behaviors

    phase 2 other completed

    1 trial

  18. Bemnifosbuvir

    Atea Pharmaceuticals

    Chronic Hepatitis C Virus

    phase 2 small molecule completed

    1 trial

  19. Benznidazole

    BRIGHT MINDS BIOSCIENCES INC.

    Trypanosoma Cruzi Infection

    phase 2 small molecule completed

    1 trial

  20. Bisphosphocin Nu-3

    Lakewood-Amedex Biotherapeutics

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  21. Bovine colostrum

    Hospital Authority, Hong Kong

    Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54

    phase 2 other completed

    1 trial

  22. Brincidofovir

    Jazz Pharmaceuticals Ireland Limited

    Cytomegalovirus Infection

    phase 2 small molecule completed

    1 trial

  23. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  24. Buffer S9b Solution for suspension for injection

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 2 small molecule active

    1 trial

  25. BufferGel

    BRIGHT MINDS BIOSCIENCES INC.

    HIV Infections

    phase 2 small molecule completed

    1 trial

  26. C3601010

    Pfizer Australia Pty Ltd

    Sepsis, Suspected or Confirmed Infections Due to Gram-Negative Pathogens Requiring Intravenous Antibiotic Treatment, Complicated Urinary Tract Infection, Blood Stream Infection, Hospital-acquired pneumonia or ventilator-associated pneumonia, Complicated Intra-abdominal Infection

    phase 2 small molecule active

    1 trial

  27. CAP-1002

    CAPRICOR THERAPEUTICS, INC.

    Covid19

    phase 2 mab completed

    1 trial

  28. CERC-002

    Avalo Therapeutics

    COVID-19 Pneumonia

    phase 2 small molecule completed

    1 trial

  29. CF 102

    Can-Fite BioPharma

    Chronic Hepatitis C

    phase 2 small molecule completed

    1 trial

  30. CF102

    Can-Fite BioPharma

    Non-alcoholic Steatohepatitis (NASH)

    phase 2 small molecule completed

    1 trial

  31. CHRONVAC-C®

    INOVIO PHARMACEUTICALS, INC.

    Chronic Hepatitis C Virus Infection

    phase 2 small molecule active

    1 trial

  32. COVAXIN(BBV152)

    Biotech Pharmaceutical Co.,

    Corona Virus Infection

    phase 2 mab completed

    1 trial

  33. COVID-19 Vaccine HIPRA

    Hipra Human Health S.L.

    COVID-19

    phase 2 mab completed

    1 trial

  34. CP101

    Finch Therapeutics Group

    Clostridium Difficile Infection

    phase 2 mab completed

    1 trial

  35. CRCFC-TEICO.SA.2022

    Verona Pharma Ireland Limited

    cystic fibrosis associated to persistent Staphylococcus aureus (including MRSA) infection

    phase 2 small molecule active

    1 trial

  36. CRV431 75mg

    Hepion Pharmaceuticals

    NASH - Nonalcoholic Steatohepatitis

    phase 2 small molecule completed

    1 trial

  37. CT-011

    Teva Pharma GmbH

    Chronic Hepatitis C

    phase 2 small molecule terminated

    1 trial

  38. CTIN816B12202

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  39. CYSTAGON 150 mg hard capsules

    The George Institute

    Infectious diseases of respiratory system (COVID-19)

    phase 2 small molecule active

    1 trial

  40. Cefiderocol

    Shionogi B.V.

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial

  41. Ceftriaxone 1000mg + doxycycline 100 mg

    Hong Kong Baptist University

    Neisseria Gonorrhoeae Infection

    phase 2 small molecule completed

    1 trial

  42. Cemiplimab

    Regeneron UK Limited

    HIV Infections

    phase 2 mab terminated

    1 trial

  43. Cemiplimab

    Regeneron UK Limited

    Hepatitis B Virus

    phase 2 mab terminated

    1 trial

  44. ChAdOx1-HBV

    Barinthus Biotherapeutics plc.

    Hepatitis B

    phase 2 mab completed

    2 trials

  45. ChAdOx1-HBV

    Barinthus Biotherapeutics plc.

    Chronic Hepatitis B

    phase 2 mab completed

    1 trial

  46. ChAdOx1-HPV

    Barinthus Biotherapeutics plc.

    HPV Infection

    phase 2 mab completed

    1 trial

  47. Chidamide Combined with NKG2D CAR-NK Cell Therapy

    The First People's Hospital of Lianyungang

    HIV (Human Immunodeficiency Virus)

    phase 2 small molecule active

    1 trial

  48. Chinese Herb

    Chinese University of Hong Kong

    COVID-19

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many infectious disease Phase II programs exist?

365 programs match both the therapeutic area and stage filters in our published index.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.